Many people are studying the rising prices of cancer drugs. A growing group of oncologists want to do something different: they want to give them a downward push.
MD Anderson Cancer Center has once again assumed its place at the top of the influential U.S. News & World Report rankings for 2015-2016.
MD Anderson Cancer Center's faculty has asked the UT System to freeze the salaries of Ronald DePinho and members of his executive team until they reach a level of parity with faculty salaries, according to a white paper presented to UT System Chancellor Bill McRaven June 14.
The FDA Oncologic Drugs Advisory Committee July 9 appears to have recommended approval for the Eli Lilly and Co. agent necitumumab.Yes, the word “appears” has indeed appeared in the previous sentence.
Is new money on the way to NCI? It's certainly been promised in President Obama's budget proposal and in the appropriations bills gestating in the House and Senate.
The House and Senate appropriations committees earlier this week passed parallel spending bills that would boost NIH budgets while eliminating the Agency for Healthcare Research Quality, a $465 million agency that plays a central role in the implementation of President Barack Obama's health care law.
A health services researcher at Memorial Sloan-Kettering Cancer Center has proposed a method for assessing whether cancer drugs are rationally priced.
NCI is opening up its contract for operations and technical support at the Frederick National Laboratory for Cancer Research for re-competition—a process that officials said will take up to two years.
ECOG-ACRIN Cancer Research Group is starting enrollment in NCI-MATCH, the most ambitious of NCI's new generation of clinical trials.
Neupogen, a drug widely used in oncology, recently received an FDA approval for boosting survival in people acutely exposed to myelosuppressive doses of radiation, also known as hematopoietic syndrome or acute radiation syndrome.
